New partner wakes to lucid PeptiDream as IPO beckons
This article was originally published in Scrip
Executive Summary
PeptiDream's new agreement with Ipsen adds to an existing quiver of deals with Big Pharma partners that should stand the Japanese bioventure in good stead for its planned initial public offering in Tokyo later this year.